Bispecific antibody for specifically neutralizing TGF-beta signal of helper T cell, pharmaceutical composition and application thereof

• Main Author: CHENG HANBING
• Format: Patent
• Language: Chinese; English
• Published: 16.03.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention relates to the technical field of biology, and particularly relates to a bispecific antibody for specifically neutralizing a TGF-beta signal of a helper T cell. The bispecific antibody at least comprises a first protein chain and a second protein chain, wherein the first protein chain comprises a part or all of the structure of a first protein functional region, and/or a part or allof the structure of a second protein functional region; the first protein functional region targets CD4; the second protein functional region targets TGF beta 1; and the optimized anti-CD4/anti-TGF-beta 1 bifunctional antibody can efficiently neutralize the TGF-beta signal of the helper T cell with high affinity, affinity and specificity. Specifically, the optimized anti-CD4/anti-TGF-beta 1 bifunctional antibody, represented in the form of IgG-(L)-ScFv, can inhibit the TGF-beta signal pathway of the helper T cell with higher neutralizing efficacy, and can achieve the same cancer inhibiting effect with lower drug conce